Lytix Biopharma will host Capital Markets Day - November 22, 2022
Lytix Biopharma (“Lytix”), is pleased to announce that it will host a Capital Markets Day for investors, analysts and media on Wednesday, November 22, 2022.
The event will be open for physical attendance in Oslo, Norway, as well as a live webcast. It is scheduled to start at 14.30 CET, and is expected to last approximately two hours, including Q&A.
Speakers will be:
* Øystein Rekdal, CEO of Lytix:
What makes Lytix' immuno-oncology technology platform stand out as unique?
* Niels Junker, Chief Physician at Herlev Hospital and investigator at the ATLAS-IT-04 proof-of-concept study:
Investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcoma – a pilot study.
* Aurélien Marabelle, Professor of Clinical Immunology, Université Paris Saclay and an internationally recognized expert on intratumoral cancer treatment:
Liver cancer: Current treatment modalities and how oncolytic molecules could play an integral role in future liver cancer treatment.
* Stephen Worsley, CBO of Lytix:
The commercial versatility of oncolytic molecules: What can LTX-315/401 bring to the immuno-oncology table/offer to the pharmaceutical industry.
Registration, for physical or virtual attendance: Before November 21, 2022, at 14.30 CET: https://www.lytixbiopharma.com/news/events/register-for-event.html
For more information, please contact:
Ole Peter Nordby, ole.peter.nordby@lytixbiopharma.com
About Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient's immune system to fight cancer. The company's technology is based on pioneering research in "host defense peptides" – nature's first line of defense towards foreign pathogens. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disrupts their cell membranes, causing immunogenic cell death and release of a patient's tumor specific antigens and immune-stimulating molecules. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells.
For more information, visit www.lytixbiopharma.com.